0001641172-25-014742.txt : 20250611 0001641172-25-014742.hdr.sgml : 20250611 20250611171821 ACCESSION NUMBER: 0001641172-25-014742 CONFORMED SUBMISSION TYPE: 5 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250611 DATE AS OF CHANGE: 20250611 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CZIRR JAMES C CENTRAL INDEX KEY: 0001260641 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 5 SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 251040902 MAIL ADDRESS: STREET 1: 4908 SOUTH ASHTON COURT CITY: SPOKANE STATE: WA ZIP: 99223 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 BUSINESS PHONE: 678-620-3186 MAIL ADDRESS: STREET 1: 4960 PEACHTREE INDUSTRIAL BOULEVARD STREET 2: SUITE 240 CITY: NORCROSS STATE: GA ZIP: 30071 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 5 1 ownership.xml 5 X0508 5 2024-12-31 0 0 0 0001133416 GALECTIN THERAPEUTICS INC GALT 0001260641 CZIRR JAMES C 4908 S. ASHTON CT. SPOKANE, WA 99223 0 0 1 0 0 Common Stock 2024-03-31 5 J 0 1000 6.00 A 763616 D Common Stock 2024-05-10 5 G 0 4400 D 759216 D Common Stock 2024-05-17 5 G 0 4400 D 754816 D Common Stock 2024-05-17 5 G 0 4400 D 750416 D Common Stock 2024-06-26 5 G 0 4400 D 746016 D Common Stock 2024-09-30 5 J 0 1000 6 A 747016 D Common Stock 2024-07-03 5 G 0 600 D 746416 D Common Stock 2024-12-19 5 G 0 5000 D 741416 D Common stock received in satisfaction of $6,000 of dividends due on Series A Convertible Preferred Stock owned by James C. Czirr pursuant to issuer's option to pay dividends in cash or common stock, at its sole discretion. The dividends were payable on 3/31/2024 and 9/30/2024. The price is the amount of the dividend divided by the number shares issued in satisfaction of the dividend. Exempt from Section 16(b) of the Securities Exchange Act pursuant to Rule 16a-9. No consideration was received for the shares, which were transferred by gift to relatives. /s/ James C. Czirr 2025-06-11